The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes it looks like an exciting new venture. Hopefully the presentation clarifies more on the funding and timeline for lab work. The 'ventures' page of the SRI website implies that SRI provide lab funding in exchange for modest equity on any successful product. If that's the case it sounds like a good deal to me. SRI obviously think that Nuvec has potential to optimise their own MGS product.
SRI undertakes client sponsored research in various areas of scientific research
Its has a system of cargo delivery (mgs) which delivers various moieties inc nanoparticles
Nuvec is also a delivery vehicle- likely to need enhancement or it will not progress (commercially)
Nuvec protects the nucleic acid from enzymatic breakdown and carries more than one rna (for example)
Mgs uses peptides to better target cells/organelles
There is some focus on eventual commercial development, although N4p has had similar collaborations with non profit organisations before
Who funds what? What are the milestones/timelines?
You would assume that SRI are not going to waste their time partnering with a company / product unless it has a certain degree of potential for commercial success. SRI clearly like what they see with Nuvec.
It is currently difficult for N4 to showcase their product to 'big pharma' so this collaboration should make it much easier to do so.
Sounds like a great step forward for N4P.
Seeing more of this one about so probably paid for with a fund raising coming
Guessing the new collaboration will fund their side of things and if its successful, will be a massive leap forward for us in the states and financial reward will come without any cost risk to us stm.
Into the silicon valley n4p rode. Looks like the best shot at moving to commercialisation. I think the market and myself were expecting this news to be combined with some financial assurance. Nigel did say in the results there is enough money for current work in progress. That is pretty vague as to what work in progress is included . Is for example this new collaboration included in the immediate expenditure forecast? If not how is it to be addressed?
The news isn't bad, but it's not news you would suddenly invest in a company for or even top up?
The share price changing news will come, but it's a long while off yet.
It's an 'ok' RNS..
But leaves the big question mark over that huge issue ..FUNDING.
We seem to be inching forward. The market clearly not over excited yet. I guess the big question hasn’t asked yet is will we share holders be recommending to others to invest. To be honest it’s not something I would do with any investment. For starters you have no idea what other peoples situations are or tolerance to risk. As far as the market goes we are still in the dark about further rounds of funding. However this is a substantial step in another direction. ‘Making good drugs better’ is a great motto for N4p. Let’s hope that becomes reality soon. Very good luck everyone
Big news emanating out of £2Million MCAP pharma N4P today. Ceo Nigel Theobald has pulled a rabbit out of the hat with a significant collaboration agreement. SRI is very well connected in the industry. Getting drugs to the clinical stage and in to the market has been their modus operandi for years. This is an impressive partnership that could yield a huge result.
Very positive news for a £2m market cap company. The upside potential is large indeed.
Exactly. SRI has advanced more than 200 drugs to clinical trials, and 25 have reached the market. This looks an excellent partnership for N4P and could be a game changer....
Good luck, Brighty
Although it will take time its a good collaboration for N4.
Agreed there is a great potential to the collaboration and it would appear our new friends are at least connected to larger Pharma companies that will help us appear on their radar.
The downside is time as this will i presume lead to a new run of lab testing starting at point a to see if the delivery systems will work together.
slowly slowly catchy monkey it would appear
Collaboration with SRI in California. Research organisation will conjugate its MGS to Nuvec in order to increase intracellular delivery to specific target cells. Could be a way forward in US with major Pharmas adopting if successful.